CN117224628A

CN117224628A - Medicine for treating chronic obstructive pulmonary disease in stable period after acute exacerbation and preparation method thereof

Info

Publication number: CN117224628A
Application number: CN202311131083.3A
Authority: CN
Inventors: 李正欢
Original assignee: First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Current assignee: First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
Priority date: 2023-09-04
Filing date: 2023-09-04
Publication date: 2023-12-15

Abstract

The invention discloses a medicine for treating chronic obstructive pulmonary disease in a stable period after acute exacerbation. The invention has the effects of tonifying qi, strengthening the body resistance, reducing phlegm, promoting blood circulation, nourishing yin and clearing heat, has the effects of relaxing bowels and purifying lung, is suitable for people in a stable period after acute exacerbation of chronic obstructive pulmonary disease, can enhance autoimmune and disease resistance, reduce acute exacerbation frequency to delay lung function deterioration and disease progression, improve respiratory symptoms and exercise endurance, and improve survival quality.

Description

Medicine for treating chronic obstructive pulmonary disease in stable period after acute exacerbation and preparation method thereof

The invention field:

the invention relates to a medicine for treating chronic obstructive pulmonary disease at a stabilization stage after acute exacerbation and a preparation method thereof, belonging to the field of medicine technology.

Background

Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is a heterogeneous pulmonary disease caused by airway inflammation such as bronchitis and/or structural abnormalities such as emphysema with persistent, progressive airflow limitation, and clinical manifestations of chronic respiratory symptoms such as dyspnea, cough, expectoration, etc. At present, COPD is the third leading cause of death worldwide, and is the seventh disease burden in the global disability-adjustedlife years (DALYs) and 2019, which is the 323 thousands of deaths from COPD and its related diseases, and 2060 is expected to be over 540 thousands of deaths all year round.

Acute exacerbations of chronic obstructive pulmonary disease (acute exacerbation of COPD, AECOPD) refer to dyspnea and/or cough and increased sputum within 14 days, which may be accompanied by shortness of breath and/or tachycardia, often associated with airway and systemic inflammatory responses caused by infection, air pollution or other factors. The pathological immune inflammatory reaction in the acute exacerbation stage causes airway spasm, increased sputum, retention and the like, seriously affects pulmonary ventilation and pulmonary ventilation, causes obvious hypoxia and dyspnea, and can often induce or combine heart failure, ischemic heart disease, arrhythmia (atrial fibrillation) and the like besides acute respiratory distress syndrome (acute respiratory distress syndrome, ARDS). Acute exacerbation is the main cause of high hospitalization rate and mortality rate, the 5-year mortality rate of discharged patients after acute exacerbation is about 50%, the frequency and degree of acute exacerbation are closely related to the progress and exacerbation of the disease, and the death risk of frequent exacerbations (more than or equal to 2 times/year) is higher. Therefore, it is important and critical how to perform relevant preventive treatment in the post-acute exacerbation stationary phase to delay lung function deterioration and reduce the frequency of acute exacerbation.

At present, the main therapeutic drugs for the stationary phase of chronic obstructive pulmonary disease are beta ₂ Receptor agonists, cholinergic receptor antagonists, and inhaled glucocorticoids, alone or in combination. The long-term inhalation of the medicines is extremely easy to generate drug resistance, and side effects such as palpitation, nausea, vomiting, abdominal pain, arrhythmia and the like can occur. The medicine can only reduce lung inflammation and relax bronchus to improve dyspnea symptoms, and cannot fundamentally improve immunity, improve lung functions and the like. The traditional Chinese medicine can strengthen body resistance and eliminate pathogenic factors fundamentally so as to achieve the effect of improving immunity and disease resistance. The prescription of the invention is based on COPD stabilizationThe traditional Chinese medicine pathogenesis rules of deficiency, phlegm, blood stasis and heat (see the doctor graduation paper of the inventor for researching and applying the pathogenesis change rules of traditional Chinese medicine in COPD, which can be searched in the known network throughout) are treated to tonify qi, strengthen body resistance, reduce phlegm, activate blood, nourish yin, clear heat, clear viscera and reduce lung, and can effectively reduce acute exacerbation frequency to delay lung function deterioration and disease progress, improve respiratory symptoms and exercise tolerance and improve the life quality by enhancing the autoimmune and disease resistance. (the slow pulmonary obstructive acute sender (AECOPD II number (patent application number: 2022104424036)) based on the rules of pathogenesis in the acute exacerbation phase of COPD has issued a notification of the authorized registration procedure.

Disclosure of Invention

The invention aims to solve the technical problem of providing a medicine for treating chronic obstructive pulmonary disease at a stabilization stage after acute exacerbation and a preparation method thereof. The invention has the effects of tonifying qi, strengthening the body resistance, resolving phlegm, promoting blood circulation, nourishing yin and clearing heat, has the effects of relaxing bowels and purifying lung, and is suitable for people in the stationary phase after acute exacerbation of chronic obstructive pulmonary disease.

In order to solve the technical problems, the invention is realized by adopting the following technical scheme:

a medicine for treating chronic obstructive pulmonary disease in the stationary phase after acute exacerbation comprises the following medicinal active ingredients in parts by weight: is prepared from 100-200 parts of ginseng, 50-150 parts of fritillaria thunbergii, 50-150 parts of semen trichosanthis, 50-150 parts of dried orange peel, 50-150 parts of poria cocos, 50-150 parts of rhizoma pinellinae praeparata, 30-90 parts of cortex moutan, 30-90 parts of red paeony root, 50-150 parts of radix scutellariae, 50-150 parts of rhizoma anemarrhenae, 10-50 parts of raw rheum officinale and 30-90 parts of raw liquorice.

The medicine for treating the acute exacerbation of chronic obstructive pulmonary disease in the stationary phase comprises the following medicinal active ingredients in parts by weight: is prepared from 120-180 parts of ginseng, 70-130 parts of fritillaria thunbergii, 70-130 parts of semen trichosanthis, 70-130 parts of dried orange peel, 70-130 parts of poria cocos, 70-130 parts of rhizoma pinellinae praeparata, 40-80 parts of cortex moutan, 40-80 parts of red paeony root, 70-130 parts of radix scutellariae, 70-130 parts of rhizoma anemarrhenae, 20-40 parts of raw rheum officinale, and 40-80 parts of raw liquorice.

In particular, the medicine for treating the chronic obstructive pulmonary disease in the stationary phase after acute exacerbation comprises the following medicinal active ingredients in parts by weight: is prepared from 150 parts of ginseng, 100 parts of fritillaria thunbergii, 100 parts of semen trichosanthis, 100 parts of dried orange peel, 100 parts of poria cocos, 100 parts of rhizoma pinellinae praeparata, 60 parts of cortex moutan, 60 parts of radix paeoniae rubra, 100 parts of radix scutellariae, 100 parts of rhizoma anemarrhenae, 30 parts of radix et rhizoma Rhei and 60 parts of radix glycyrrhizae.

The preparation method of the medicine for treating the chronic obstructive pulmonary disease in the post-acute exacerbation stable phase comprises the steps of weighing all the medicinal materials according to a proportion, combining the medicinal materials with pharmaceutically acceptable auxiliary materials in the medicine, and processing the medicinal materials according to a conventional preparation method to prepare corresponding medicinal preparations.

Specifically, the preparation method of the medicine for treating the chronic obstructive pulmonary disease in the post-acute exacerbation stationary phase comprises the steps of weighing the medicinal materials according to the proportion of the formula, adding water for soaking, decocting, mixing the decoctions, uniformly mixing, concentrating, filtering while hot, concentrating the filtrate into extract, combining with pharmaceutically acceptable auxiliary materials in the medicine, and processing according to the conventional preparation method to prepare the corresponding oral pharmaceutical preparation.

The oral pharmaceutical preparation comprises a soft extract, granules, hard capsules, tablets or oral liquid.

The decoction is prepared by the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in 8 times of water for 0.5 hour, decocting the medicinal materials for 0.5 hour, adding the raw rhubarb according to the prescription proportion, decocting the medicinal materials for 0.5 hour, collecting decoction, adding 8 times of water into dregs, decocting the dregs for 1 hour, mixing the two decoctions, uniformly mixing, concentrating the mixture into an extract with the relative density of 1.15-1.20 when the mixture is hot, filtering the hot mixture, concentrating the filtrate to 70 ℃, adding refined honey with the relative density of 20%, adding the same times of warm water, stirring and dissolving the mixture, slowly adding the mixture into the extract, stirring the mixture uniformly, continuously heating the mixture with slow fire to obtain the ointment, and obtaining the ointment when a small amount of the ointment can be horizontally pulled into filaments or the ointment is dripped on paper without water marks.

The aforementioned granules were prepared as follows: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in 10 times of water for 0.5 hour, decocting for 1 hour, adding the raw rhubarb according to the prescription proportion, decocting for 1 hour, collecting decoction, adding 10 times of water into dregs, decocting twice, each time for 0.5 hour, mixing the three decoctions, uniformly mixing, concentrating into 80% of the original medicinal liquid, filtering while the medicinal liquid is hot, concentrating the filtrate to 70 ℃ relative density of extract with 1.15-1.20, drying the extract at 70 ℃, crushing the extract into fine powder to obtain dry extract, taking 1 part of dry extract and 20% sucrose, granulating with 80% ethanol as a wetting agent, granulating, drying at 60 ℃, sieving with a 12-mesh sieve for 1 time, and sieving with a 60-mesh sieve to obtain the granule.

The aforementioned capsules were prepared as follows: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in 12 times of water for 0.5 hour, decocting for 0.5 hour, adding the raw rhubarb according to the prescription proportion, decocting for 0.5 hour, collecting decoction, adding 12 times of water into dregs, decocting twice, each time for 0.5 hour, combining the three decoctions, uniformly mixing, concentrating into 70% of the original medicinal liquid, filtering when the medicinal liquid is hot, concentrating the filtrate into an extract with relative density of 1.15-1.20 at 70 ℃, drying at 70 ℃ into dry extract, pulverizing into fine powder, adding 10% of starch and 3% of microcrystalline cellulose, uniformly mixing, granulating with 75% of ethanol, drying, granulating, and filling into capsules to obtain the Chinese medicinal capsule.

The aforementioned tablets were prepared as follows: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in water for 0.5h, decocting for 1h, adding the raw rhubarb according to the prescription proportion, decocting for 1h, collecting decoction, adding water for 6 times of decoction for 1.5 h, mixing the three decoction, concentrating into an extract with the relative density of 1.15-1.20 when the raw medicinal liquid is 80%, filtering when the filtrate is concentrated to 70 ℃, drying the extract at 70 ℃, crushing the extract into fine powder to obtain a dry extract, taking the dry extract, adding 15% starch and 1% talcum powder, mixing uniformly, granulating with 10% starch slurry as a wetting agent, drying, tabletting, and film coating to obtain the tablet.

Compared with the prior art, the invention has the following beneficial effects:

the medicine for treating chronic obstructive pulmonary disease in the stable period after acute exacerbation of the invention is prepared from ginseng, fritillaria thunbergii, semen trichosanthis, dried orange peel, poria cocos, rhizoma pinellinae praeparata, cortex moutan, radix paeoniae rubrathe, radix scutellariae, rhizoma anemarrhenae, radix rheum officinale and radix glycyrrhizae. The properties and efficacy of each component are as follows: the Ginseng radix is dried root and rhizome of Panax ginseng C.A. Mey; collected in autumn, washed, dried in the sun or baked. Cultivated commonly known as "Yuanshen"; sowing under-forest mountain ginseng naturally growing in a mountain forest wild state, which is known as seed sea; sweet and slightly bitter, slightly warm in nature; spleen, lung, heart and kidney meridians; has effects of invigorating primordial qi, recovering pulse, relieving depletion, invigorating spleen, benefiting lung, promoting salivation, nourishing blood, tranquilizing mind, and improving intelligence; can be used for treating asthenia, listlessness, cold limbs, weak pulse, spleen deficiency, anorexia, lung deficiency, asthma and cough, body fluid consumption, thirst, internal heat, thirst, deficiency of qi and blood, deficiency of both long-term illness, palpitation, insomnia, sexual impotence, and cold womb. Bulbus Fritillariae Thunbergii is dried bulb of Bulbus Fritillariae Thunbergii Fritillaria thunbergii Miq of Liliaceae; bitter taste and cold nature; enter lung and heart meridians; has effects of clearing heat, resolving phlegm, relieving cough, removing toxic substance, resolving hard mass, and resolving carbuncle; can be used for treating cough due to wind-heat, phlegm-fire, pulmonary abscess, acute mastitis, scrofula, and skin sore. Semen Trichosanthis is mature seed of Trichosanthes genus Trichosanthes kirilowii maxim of Cucurbitaceae family or t.rosthornii Harms; sweet in taste and cold in nature; enter lung meridian; has effects of clearing away heart-fire, relieving restlessness and promoting diuresis; can be used for treating thirst due to heat-induced diseases (such as fever or heart fire), difficult urination, stranguria due to urinary tract infection, and pain during urination. Pericarpium Citri Tangerinae is dried mature pericarp of Citrus reticulata Blanco Citrus reticulata Blanco and its cultivar; bitter and pungent taste and warm nature; enter lung and spleen meridians; has effects of regulating qi-flowing, invigorating spleen, eliminating dampness and resolving phlegm; can be used for treating abdominal distention, anorexia, vomiting and diarrhea, cough with excessive phlegm. Poria is dry sclerotium of Polyporaceae fungus Poria cocos (Schw.) Wolf; sweet and light in taste and neutral in nature; return to heart, lung, spleen and kidney meridians; has effects in promoting diuresis, eliminating dampness, invigorating spleen, and calming heart; can be used for treating edema, oliguria, phlegm retention, palpitation, spleen deficiency, anorexia, loose stool, diarrhea, uneasiness, palpitation, and insomnia. Rhizoma Pinelliae Preparata is processed product of rhizoma Pinelliae; pinellia ternate is a dried tuber of the plant Pinellia ternate Pinellia ternata (thunder.) of the family arisaemaceae; pungent taste and warm nature; spleen, stomach and lung meridian; has effects of eliminating dampness and phlegm; can be used for treating cough and asthma with excessive phlegm, phlegm retention, palpitation, dizziness, and headache. Cortex moutan is dried root bark of Paeonia suffruticosa Paeonia suffruticosa Andr of Ranunculaceae; digging root in autumn, removing fine root and silt, peeling root bark, sun drying or scraping coarse bark, removing wood core, sun drying; bitter and pungent taste and slightly cold nature; return to heart, liver and kidney meridians; has effects of clearing heat, cooling blood, promoting blood circulation, and removing blood stasis; is used for treating heat entering nutrient blood, toxic heat, speckle, hematemesis, epistaxis, night fever, early cooling, no sweat, bone steaming, amenorrhea, dysmenorrhea, traumatic injury, carbuncle, swelling and sore. Radix Paeoniae Rubra is dried root of Pall of Paullinia herbaceous peony Paeonia lactiflora or Paeonia veitchii Lynch of radix Paeoniae Rubra; bitter taste and slightly cold nature; enter liver meridian; has effects of clearing heat, cooling blood, removing blood stasis and relieving pain; can be used for treating heat entering nutrient blood, toxic heat, speckle, hematemesis, epistaxis, conjunctival congestion, swelling and pain, liver Yu Xie pain, amenorrhea, dysmenorrhea, abdominal mass, abdominal pain, traumatic injury, carbuncle, swelling and sore. The radix Scutellariae is dry root of radix Scutellariae Scutellaria baicalensis Georgi of Labiatae; digging in spring and autumn, removing fibrous root and silt, sun drying, removing coarse skin, and sun drying; bitter taste and cold nature; the lung channel, the gallbladder channel, the spleen channel, the large intestine channel and the small intestine channel; has effects of clearing heat, eliminating dampness, purging pathogenic fire, removing toxic substances, stopping bleeding, and preventing miscarriage; can be used for treating damp-heat, summer-heat, chest distress, emesis, damp-heat distention and fullness, dysentery, jaundice, cough due to lung heat, polydipsia due to high fever, hematemesis, epistaxis, carbuncle, swelling, sore, and fetal movement. Rhizoma anemarrhenae is dried rhizome of rhizoma anemarrhenae Anemarrhena asphodeloide Bge of Liliaceae; collected in spring and autumn, removed fibrous roots and sediment, dried in the sun, and called as 'rhizoma anemarrhenae'; or removing skin, and sun drying; bitter and sweet in taste, cold in nature; enter lung, stomach and kidney meridians; has effects of clearing heat, purging pathogenic fire, nourishing yin, and moistening dryness; can be used for treating exogenous febrile disease, hyperpyrexia, polydipsia, lung heat, dry cough, hectic fever, internal heat, diabetes, constipation, and intestinal dryness. The radix et rhizoma Rhei is dried root and rhizome of Rheum palmatum L of Polygonaceae, R.tannagicum Maxim.ex Bal. Or R.offictile bail 1; bitter taste and cold nature; spleen, stomach, large intestine, liver and pericardium meridian; has effects of purging pathogenic accumulation, clearing heat, purging pathogenic fire, cooling blood, removing toxic substance, removing blood stasis, dredging channels, promoting diuresis and eliminating jaundice; can be used for treating constipation due to excessive heat accumulation, hematemesis, epistaxis, conjunctival congestion, pharyngeal swelling, carbuncle, furuncle, acute carbuncle, abdominal pain, blood stasis, amenorrhea, puerperal stagnation, traumatic injury, damp-heat dysentery, jaundice, dark urine, stranguria, and edema; it is used for treating burn and scald. The raw Glycyrrhrizae radix is dry root and rhizome of Glycyrrhrizae radix Glycyrrhiza uralensis Fisch of Leguminosae, glycyrrhiza glabra G.Inflata bat. Or Glycyrrhiza glabra G.glabra L; digging in spring and autumn, removing fibrous root, and sun drying; sweet in taste and neutral in nature; return to heart, lung, spleen and stomach meridians; has effects of invigorating spleen, replenishing qi, removing toxic substances, eliminating phlegm, relieving cough, relieving spasm, relieving pain, and harmonizing the above materials; can be used for treating weakness of spleen and stomach, listlessness, debilitation, palpitation, short breath, cough with excessive phlegm, abdominal pain, limb spasm, carbuncle, swelling, sore and toxic materials, and relieving drug toxicity and intensity.

And (3) square solution:

under the guidance of the pathogenesis rule of the chronic obstructive pulmonary disease, the subject group creates a prescription for the stable phase of the acute exacerbation of the chronic obstructive pulmonary disease, namely the prescription AECOPD I (chronic obstructive pulmonary disease stability) of the invention. Aiming at the pathogenesis characteristics of 'deficiency' in the stabilization period after acute exacerbation of chronic obstructive pulmonary disease, ginseng in the formula is used as a monarch drug for tonifying qi, strengthening body resistance, clearing heat and resolving phlegm. The ginseng is an essential medicine for tonifying lung, can improve symptoms such as shortness of breath, dyspnea, and the like, can tonify spleen qi and lung qi, can comprehensively strengthen healthy qi, and can avoid healthy qi deficiency from being affected by evil to induce acute exacerbation. Zhe Bei mu is good at clearing heat and resolving phlegm, and reducing lung qi. Zhejiang fritillary bulb in Ben Cao Zheng (materia Medica): most reducing phlegm-qi, and good at resolving stagnation. Semen trichosanthis, dried orange peel, poria cocos, rhizoma pinellinae praeparata, cortex moutan and radix paeoniae rubra are used as ministerial drugs for clearing heat, cooling blood and activating blood, and rhizoma anemarrhenae and radix scutellariae are used as ministerial drugs for nourishing yin and clearing heat. Wherein, the semen trichosanthis has the functions of clearing heat and resolving phlegm, and clearing viscera and lung. Fructus Trichosanthis, in Ben Cao gang mu (compendium of materia Medica): "Lung moistening dryness, reducing fire, treating cough, eliminating phlegm stagnation, … … benefiting large intestine". Ban Xia is the key herb for eliminating dampness and resolving phlegm. Pinellia ternate, mainly used for the secret key: phlegm-resolving … … eliminating phlegm and saliva in chest. Zhi mu is bitter and cold in flavor, and can clear lung fire, nourish yin and moisten lung. Bai Huang is cold in nature, enters lung meridian, and good at clearing lung fire and drying dampness. Ben Cao Zheng (Ben Cao Zheng): the dry person can clear the fire of upper energizer, clear phlegm and promote qi circulation, and relieve dyspnea and cough. The lung is produced Huang Tongfu and heat conduction is carried out from stool to be used as adjuvant drug. Licorice root, radix Glycyrrhizae regulates the action of other drugs as a guiding drug. Therefore, the AECOPD I formula can comprehensively aim at the regular characteristics of the pathogenesis of the chronic obstructive pulmonary disease in the stable period after the acute exacerbation, has the effects of tonifying qi, strengthening the body resistance, reducing phlegm, promoting blood circulation, nourishing yin and clearing heat, and has the effects of clearing viscera and purifying lung.

Description of the drawings:

fig. 1: wien plot (COPD disease target and AECOPD square action target);

fig. 2: traditional Chinese medicine-disease-target point network diagram (AECOPD-I: chronic obstructive pulmonary stability prescription; COPD: chronic obstructive pulmonary disease)

Fig. 3: the target gene proteins are mutually mapped;

fig. 4: carrying out interaction connection statistics on target genes;

fig. 5: enrichment analysis of target gene Biological Process (BP);

fig. 6: a gene pathway of interest (KEGG) enrichment analysis;

fig. 7: TNF signaling pathway.

Fig. 8-1: typical case 1 (PDF signature version);

fig. 8-2: typical case 1 (PDF signature version);

fig. 9-1: typical case 2 (PDF signature version);

fig. 9-2: typical case 2 (PDF signature version);

fig. 10-1: typical case 3 (PDF signature version);

fig. 10-2: typical case 3 (PDF signature version);

Detailed Description

The invention is further illustrated by the following examples, which are not intended to be limiting.

Example 1.

Prescription: is prepared from ginseng 15g, fritillaria thunbergii 10g, snakegourd seed 10g, dried orange peel 10g, poria cocos 10g, prepared pinellia tuber 10g, root bark of tree peony 6g, red paeony root 6g, raw baikal skullcap root 10g, rhizoma anemarrhenae 10g, raw rhubarb 3g and raw licorice root 6g.

The process comprises the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription, soaking the medicinal materials in 8 times of water for 0.5 hour, decocting for 1 hour, adding the raw rhubarb according to the prescription, decocting for 0.5 hour, collecting decoction, decocting the residues in 8 times of water for 1 hour, and combining the two decoctions to obtain the water decoction.

The usage amount is as follows: the decoction is administered orally for three times, and can be administered in the morning, in the middle and at night (before and after meals).

Example 2.

The process comprises the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription, soaking the medicinal materials in 8 times of water for 0.5 hour, decocting for 0.5 hour, adding the raw rhubarb according to the prescription, decocting for 0.5 hour, collecting decoction, adding 8 times of water into dregs, decocting for 1 hour, mixing the two decoctions, uniformly mixing, concentrating into an extract with the relative density of 1.15-1.20 when the raw medicinal liquid is 80%, filtering while the filtrate is hot, concentrating the filtrate to 70 ℃, adding refined honey with the relative density of 20%, adding the same amount of warm water, stirring for dissolving, slowly adding the extract, stirring uniformly, continuously heating with slow fire to obtain the extract, and obtaining the decoction when a small amount of the extract can be horizontally pulled into filaments or is dropped on paper without water trace.

The usage amount is as follows: orally administered, 20g each time before and after meals, after dissolving in hot water; can also be directly swallowed.

Example 3.

Prescription: 10g of ginseng, 5g of fritillaria thunbergii, 5g of semen trichosanthis, 5g of dried orange peel, 5g of poria cocos, 5g of rhizoma pinellinae praeparata, 3g of cortex moutan, 3g of radix paeoniae rubra, 5g of radix scutellariae, 5g of rhizoma anemarrhenae, 1g of radix rheum officinale and 3g of radix glycyrrhizae.

The process comprises the following steps: weighing the raw materials except for the raw rhubarb according to the prescription, soaking the raw rhubarb in 10 times of water for 0.5 hour, decocting for 1 hour, adding the raw rhubarb according to the prescription, decocting for 1 hour, collecting decoction, adding 10 times of water into dregs, decocting twice for 0.5 hour each time, mixing the three decoctions, uniformly mixing, concentrating into 80% of the original liquid medicine, filtering while the liquid medicine is hot, concentrating the filtrate into extract with relative density of 1.15-1.20 at 70 ℃, drying the extract at 70 ℃,

pulverizing into fine powder to obtain dry extract, granulating 1 part of dry extract with 20% sucrose and 80% ethanol as wetting agent, granulating, drying at 60deg.C, sieving with 12 mesh sieve for 1 time, and sieving with 60 mesh sieve to obtain granule.

The usage amount is as follows: taken orally 15g (before and after meals) 3 times a day.

Example 4.

Prescription: 20g of ginseng, 15g of fritillaria thunbergii, 15g of semen trichosanthis, 15g of dried orange peel, 15g of poria cocos, 15g of rhizoma pinellinae praeparata, 9g of cortex moutan, 9g of radix paeoniae rubra, 15g of radix scutellariae, 15g of rhizoma anemarrhenae, 5g of radix rheum officinale and 9g of radix glycyrrhizae.

The process comprises the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription, soaking the medicinal materials in 12 times of water for 0.5 hour, decocting for 0.5 hour, adding the raw rhubarb according to the prescription, decocting for 0.5 hour, collecting decoction, adding 12 times of water into dregs, decocting twice, each time for 0.5 hour, combining the three decoctions, uniformly mixing, concentrating into 70% of the original medicinal liquid, filtering while the medicinal liquid is hot, concentrating the filtrate into an extract with relative density of 1.15-1.20 at 70 ℃, drying at 70 ℃ into dry extract, pulverizing into fine powder, adding 10% of starch and 3% of microcrystalline cellulose, uniformly mixing, granulating with 75% of ethanol, drying, granulating, and filling into capsules to obtain capsules.

The usage amount is as follows: is administered by soaking in boiled water, and can be administered 2g (before and after meals) 3 times a day.

Example 5.

Prescription: prescription: 15g of ginseng, 12g of fritillaria thunbergii, 8g of semen trichosanthis, 8g of dried orange peel, 8g of poria cocos, 8g of rhizoma pinellinae praeparata, 4g of cortex moutan, 4g of radix paeoniae rubrathe, 8g of radix scutellariae, 8g of rhizoma anemarrhenae, 2g of radix et rhizoma rhei and 5g of radix glycyrrhizae.

The process comprises the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription, soaking the medicinal materials in 6 times of water for 0.5 hour, decocting for 1 hour, adding the raw rhubarb according to the prescription, decocting for 1 hour, collecting decoction, adding 6 times of water into dregs, decocting for 1.5 hours, mixing the three decoctions, uniformly mixing, concentrating into 80% of the original medicinal liquid, filtering when the filtrate is concentrated to an extract with relative density of 1.15-1.20 at 70 ℃, drying the extract at 70 ℃, crushing the extract into fine powder to obtain a dry extract, taking the dry extract, adding 15% of starch and 1% of talcum powder, uniformly mixing, granulating with 10% of starch slurry as a wetting agent, drying, tabletting, and coating with a film to obtain the tablet.

Example 6.

Prescription: prescription: 15g of ginseng, 10g of fritillaria thunbergii, 10g of semen trichosanthis, 10g of dried orange peel, 10g of poria cocos, 10g of rhizoma pinellinae praeparata, 6g of cortex moutan, 6g of radix paeoniae rubrathe, 10g of radix scutellariae, 10g of rhizoma anemarrhenae, 3g of radix et rhizoma rhei and 6g of radix glycyrrhizae.

The process comprises the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription, adding 8 times of water for soaking for 1 hour, adding the raw rhubarb according to the prescription for decocting for 0.5 hour, collecting decoction, adding 8 times of water for decocting for 1 hour, mixing three times of decoction, uniformly mixing, concentrating into 80% of the original medicinal liquid, filtering while the hot, concentrating the filtrate into extract with relative density of 1.05-1.10 at 60 ℃, adding 10% of xylitol, stirring uniformly, standing for 24 hours, centrifuging, filtering, adding 1000ml of distilled water into the filtrate for dilution, and packaging to obtain the oral liquid.

The usage amount is as follows: is orally administered once a day (before and after meals), 20ml each time, and directly administered.

More basic and clinical studies are performed in the early stage of the invention, and the following are part of the research results of the invention:

1. network pharmacological analysis

Based on the compound research thought of traditional Chinese medicine of systematic pharmacology, the applicant firstly selects representative medicaments of ginseng, fritillary bulb, moutan bark and baical skullcap root aiming at the basic pathogenesis characteristics of deficiency, phlegm, blood stasis and heat of the traditional Chinese medicine from the prescription (AECOPD I) respectively for network pharmacology analysis.

1. Searching and screening effective components and targets of traditional Chinese medicine

The effective components and targets of the traditional Chinese medicine are searched by utilizing a pharmacological database of a traditional Chinese medicine system and an analysis platform TCMSP (https:// old. TCMSP-e.com/TCMSP. Php), and screening conditions are set: the Oral Bioavailability (OB) is more than 30%, and the drug-like property (DL) is more than 0.18, and the effective components of radix Scutellariae, bulbus Fritillariae Thunbergii, cortex moutan, and radix Ginseng are respectively 36, 7, 11, and 22 (see Table 1 for details). Screening out target points of the above effective components from TCMSP database, wherein 342 radix Scutellariae, 50 Bulbus Fritillariae Thunbergii, 201 cortex moutan, and 194 radix Ginseng (see Table 2 for details).

TABLE 1 Chinese medicinal composition of the invention

TABLE 2 target points of Chinese medicinal components

2. Searching and screening disease targets

Screening disease targets using disease database GeneCards (https:// www.genecards.org /), setting screening conditions: correlation score (Release score) > 23.0, 1037 genes associated with COPD were retrieved and screened from GeneCards (see Table 3 for details).

TABLE 3 target for COPD disease

3. Acquisition of target Gene (target)

The intersection of the target spot of the active ingredient of the drug and the disease target spot is taken by using an online tool Venn (http:// bioinformation. Psb. Ugent. Be/webtools/Venn /), and 113 target genes are obtained as shown in figure 1. The obtained target gene may be a main acting target point for clinical curative effect of traditional Chinese medicine components contained in the prescription (AECOPD I prescription) aiming at the stabilization period after COOPD acute exacerbation.

4. Drawing Chinese medicine-disease-target point network diagram

The Cytoscape software is used for drawing an action network diagram (shown in figure 2) of a traditional Chinese medicine component target spot and a Chronic Obstructive Pulmonary Disease (COPD) disease target spot of the formula (AECOPD I formula).

5. Mapping protein interaction networks

The protein interaction network is drawn for the 113 target genes by using an online tool String (https:// cn. String-db. Org /) as shown in figure 3, and then the node connection condition of each protein in the protein interaction network is calculated and drawn by using program software R. As shown in FIG. 4, the most connected nodes in the protein interaction network are IL-6, AKT1, IL-1B, VEGFA, CASP3, PTGS2, JUN, MMP9, ESR1, HIF1A and the like, and the number of the connected nodes is 92, 89, 85, 83, 81, 80, 79, 76, 75 and 75 respectively.

6. Functional enrichment analysis

The GO function enrichment of the target gene by using an online database DAVID (https:// DAVID. Ncifcrf. Gov /) is shown in table 4 and figure 5, and the target gene participates in biological processes such as inflammatory reaction, lipopolysaccharide reaction, anoxic reaction and the like inside and outside the cell mainly by means of combination with protein, transcription factor and the like.

TABLE 4 target Gene biological Process (GO) enrichment analysis

7. Pathway enrichment analysis

As shown in Table 5 and FIG. 6, the KEGG pathway enrichment analysis of the target gene by using the DAVID online database is mainly carried out on the target gene in the PI3K-Akt signaling pathway (hsa 04151), influenza A (hsa 05164), TNF signaling pathway (hsa 04668), MAPK signaling pathway (hsa 04010), HIF-1 alpha signaling pathway (hsa 04066) and other signaling pathways.

TABLE 5 target Gene pathway (KEGG) enrichment analysis

8. Summary analysis

The target gene IL6 codes for cytokines which play a role in inflammation and B cell maturation, and is produced at acute and chronic inflammation sites, and the transcription of inflammation-related proteins is induced through IL-6 alpha receptors, and the target gene IL6 relates to a plurality of pathophysiological processes related to inflammation and participates in the defense reaction of pathogenic microorganisms. PTGS2 is involved in the biosynthesis of prostaglandins involved in inflammation and mitosis. CASP3 is associated with T, B cell homeostasis and plays a critical role in the execution phase of apoptosis. CXCL8 encoded proteins are CXC chemokine family members, are secreted by neutrophils, are the main mediators of inflammatory response, guide neutrophils to the site of infection, play a role in the pathogenesis of bronchiolitis, a common respiratory disease caused by viral infection, and the like. The target genes are mainly enriched in the PI3K-Akt signal pathway, TNF signal pathway, MAPK signal pathway, HIF-1 alpha signal pathway, toll-like receptor signal pathway, complement and coagulation cascade and other signal pathways, and are mostly closely related to immune inflammation of host defenses against pathogens. For example, TNF can induce a variety of intracellular signaling pathways including apoptosis and survival, inflammation, and immunity. TNFR2 signaling activates NF-. Kappa.B pathways, including the PI 3K-dependent NF-. Kappa.B pathway, the JNK pathway, etc. (as shown in FIG. 7, red represents a target gene enriched in this pathway).

As can be seen, the target gene is mostly related to anti-inflammatory reaction and immune reaction, and the formula (AECOPD I) can play a role through the related biological processes and pathways. Therefore, the results of the network pharmacological analysis revealed that: the prescription of the invention is used for the stabilization period after acute exacerbation of chronic obstructive pulmonary disease, has the potential effects of improving organism immunity, inhibiting inflammatory injury and the like, and can reduce acute exacerbation frequency to delay the deterioration of pulmonary function and the progression of illness, improve respiratory symptoms and exercise endurance, and improve the quality of life.

2. Typical cases

The prescription of the invention, namely the AECOPD I prescription (slow pulmonary resistance stabilizing prescription), is applied to the emergency department comprehensive ward of the first affiliated hospital of Guizhou traditional Chinese medicine university for 5+ years, has definite curative effect, and is attached to typical case 3:

typical case 1 (see fig. 8-1, 8-2 for details): patient Mao Mou, identification card number: 522427 6611, hospitalization number: 52187819A, 59 years old, aggravated wheezing with shortness of breath for 3 days due to "cough, expectoration for 22+ years" was received from emergency treatment into the general ward of our hospital at 8 months of 2022.

Admission and checking: p107 times/min, spO2 50% (no oxygen uptake). High sleeper position, moderate cyanosis of lips, emphysema, shortness of breath, auscultation of full of phlegm and wheezing sounds of both lungs.

Auxiliary inspection: bedside electrocardiograph: the P-wave is high-pointed and the T-wave is changed. Blood gas analysis shows: pH 7.323,pCO261.2mmHg,pO2 84.2mmHg,Lac 3.24mmol/L. NT-proBNP shows: 11626.2pg/mL. Respiratory virus chip shows: influenza virus weak positive (±). Lung function: extremely severe mixed ventilation dysfunction; severe limitation of small airway function; MVV severe decline; the diffuse function is slightly reduced. Heart color Doppler ultrasound: pulmonary arterial hypertension (moderate). Chest CT: chronic bronchitis, emphysema, multiple inflammations of the lower lobes of the double lung, the upper lobes of the left lung and the middle lobe of the right lung.

Admission diagnosis: 1. acute exacerbation phase of chronic obstructive pulmonary disease (carbon dioxide retention, respiratory acidosis); 2. chronic pulmonary heart disease (heart is not large, sinus rhythm, heart function class III)

Hospitalization: on the basis of the conventional general treatment of Western medicine, the AECOPD II prescription (slow lung-blocking acute hair-growing prescription) is firstly given for clearing heat and resolving phlegm, promoting blood circulation and removing blood stasis, strengthening body resistance and tonifying deficiency. After the patient takes the AECOPD II prescription, the patient has no cough, expectoration, wheezing and shortness of breath in the period of 16 days of 2022, and the acute exacerbation of the chronic obstructive pulmonary disease is basically controlled and gradually changes into a stable period. The patients have red tongue, yellow and greasy coating and smooth and rapid pulse, and the prescription of the invention (AECOPD I formula) (example 1) is prepared by taking the methods of tonifying qi, strengthening healthy energy, reducing phlegm, promoting blood circulation, nourishing yin and clearing heat to consolidate curative effect, stabilize illness state, prevent relapse (strengthen autoimmunity and disease resistance, prevent illness state progress, improve respiratory symptoms and the like).

The patient has no cough, expectoration, wheezing, shortness of breath, red tongue, thin and yellow tongue coating and slippery and rapid pulse after day 19 of year 08 of 2022. Checking: the vital signs are stable, and SpO2 is 96% (no oxygen inhalation). The lung does not smell wheeze. Patients were stable in disease without recurrence and relapse after taking the prescription "AECOPD I formula" of the invention (example 1), and were treated effectively and discharged. The prescription of the invention (AECOPD I prescription) (example 1) is prescribed to be taken orally by continuing the traditional Chinese medicine outside the hospital to strengthen the autoimmune and disease resistance, reduce the acute exacerbation frequency to delay the worsening of the lung function and the disease progression, improve the respiratory symptoms and the exercise endurance and improve the life quality.

Typical case 2 (see fig. 9-1, 9-2 for details): patient Song Mou, identification card number: 520103 x 0411, hospitalization number: 5218921 men, 64 years old, develop severe cases of wheezing with coughing and shortness of breath for 10+ years, and receive emergency calls from the intensive care unit of our hospital at day 08 and 12 of 2022.

Admission and checking: p:121 times/min, R:26 times per minute, spO2, 84% (no oxygen uptake). The pharyngeal congestion and the thoracic cage are in barrel shape, intercostal spaces are widened, the respiratory distress, the left lower lung percussion sound, the auscultation of the respiratory sound of the two lower lungs are weakened, the respiratory sound of the two lungs is thick, and the middle region of the two lungs is audible and dry and wet. 141 times/min heart rate, irregular rhythm, enhanced heart sounds and unequal first heart sounds.

Auxiliary inspection: bedside electrocardiograph: rapid atrial fibrillation (141 beats/min). Blood gas analysis shows: PH 7.415,pCO2 28.5mmHg,pO2 52.6mmHg,Lac 2.59mmol/L. NT-proBNP:4033.9pg/ml. Chest CT shows: considering a double lung multiple infection, pulmonary oedema remains to be expelled. Equal volume of effusion in bilateral chest and partial atelectasis in the lower two lungs.

Admission diagnosis: 1. acute exacerbation phase of chronic obstructive pulmonary disease (type i respiratory failure); 2. arrhythmia (Rapid atrial fibrillation)

Hospitalization: based on the conventional general treatment of Western medicine, the recipe AECOPD II (slow lung resistance acute onset) and the formula atrial fibrillation stop I are orally taken by taking the methods of clearing heat and resolving phlegm, purging lung and relieving asthma, purging fire and removing stasis and nourishing qi and yin. After the treatment, the cough and the expectoration of the patient are relieved before the day 19 of the year 08 of 2022, the wheeze and the shortness of breath are improved before the patient is cured, and the acute exacerbation of the chronic obstructive pulmonary disease is basically controlled and gradually changed into a stable phase. The patients have red tongue with yellow and greasy coating and smooth and rapid pulse, and the prescription of the invention (AECOPD I formula) (example 1) is prepared by taking the methods of tonifying qi, strengthening healthy energy, reducing phlegm, promoting blood circulation, nourishing yin and clearing heat to consolidate curative effect, stabilize illness state, prevent relapse (strengthen autoimmune power, resist disease, prevent illness progress, improve respiratory symptoms and the like). The patient complains about cough, expectoration, wheezing, shortness of breath, red tongue, thin and yellow coating and slippery and rapid pulse after day 27 of year 08 2022. Checking: the vital signs are stable, the mind is clear, the spirit is fair, and the lung is not smelled and the dry and wet type is calm. After patients take the prescription AECOPD I (example 1) of the invention, the patients have no cough, expectoration and wheezing, no smell of the two lungs and dry and wet type of the tongue is red, the tongue coating is thin and yellow, the pulse is slippery and rapid, the vital signs of the checked body are stable, spO2 is 97 percent (no oxygen inhalation), so the illness state is stable, no recurrence and repetition are caused, the treatment is effective and the patients are discharged, and the patients are ordered to continue taking the traditional Chinese medicine prescription AECOPD I (example 1) of the invention outside the hospital to strengthen the autoimmunity and the disease resistance, reduce the frequency of acute exacerbation to delay the deterioration of the lung function and the progress of the illness state, improve the respiratory tract symptoms and the exercise endurance and improve the survival quality.

Typical case 3 (see fig. 10-1, 10-2 for details): patient Zhang Mou, identification card number: 522101 x 3630, hospitalization number: 52190996A, 71 years old, aggravated dyspnea 1+ month due to "wheezing shortness of breath 10+ years" was received from emergency treatment into the I's comprehensive ward at month 08 of 2022, 23.

Admission and checking: p:113 times/min, R:24 times per minute, spO2 was 89% (no oxygen uptake). The double lung percussion is clear, auscultates the double lung breathing and has thick sound absorption, but does not smell and obviously dry and wet sound. Auxiliary inspection: bedside electrocardiograph: sinus tachycardia. Blood gas analysis shows: pH 7.364,pCO2 49.2mmHg,pO2 60.5mmHg. NT-proBNP shows: 901.2pg/mL. Respiratory viruses: mycoplasma pneumoniae positive, adenovirus positive. Sputum culture + identification: klebsiella oxytoca. Heart ultrasound: pulmonary artery broadening. Chest CT shows: chronic bronchitis, emphysema of the double lung, and large bubbles of the double lung and multiple lung. The lower right lung has a slight inflammatory change.

Admission diagnosis: 1. stationary phase of chronic obstructive pulmonary disease; 2. arrhythmia (sinus tachycardia)

Hospitalization: the patients are hospitalized in 'people hospitals in cloud and rock areas' before being admitted, cough and expectoration of the patients are relieved before cough and expectoration are improved before wheezing and shortness of breath are improved after general treatment of Western medicine for nearly 1 month, and acute exacerbation of chronic obstructive pulmonary disease is basically controlled to be changed into a stable period. However, after discharge, patients still feel mild wheezing and shortness of breath, and the patients are especially motivated, with the discomfort of obvious night sweat, limb weakness, hypodynamia and the like, and then visit the hospital again. The patient's tongue is dark red, the tongue coating is yellow and thick, the pulse is smooth and rapid, and after 23 days of 2022, 08 and 23 days of hospital admission, the recipe "AECOPD I formula" (example 1) is given to the invention to consolidate curative effect, stabilize illness state, prevent recurrence (enhance autoimmune power and disease resistance, prevent illness progress, improve respiratory symptoms, etc.).

Patients in 28 days of 2022, 08, do not complain about wheezing, shortness of breath, complain about night sweat and limb weakness are relieved compared with those in hospital. Checking: the lung breathes with clear sound, does not smell and dry and wet type rales, and has no pleural fricatives. So the Chinese medicine is orally taken for treating the AECOPD I prescription (example 1) of the invention. The patient has dark red tongue with no coating in the middle of the tongue and yellow and greasy coating at the root of the tongue, and slippery and rapid pulse. The syndrome differentiation belongs to "phlegm-heat accumulating in lung, qi and yin impairment", and the treatment is carried out by taking the "heat clearing and phlegm resolving, yin nourishing and body fluid generating" as a method, and continuing to administer the "AECOPD No. I prescription" to consolidate curative effects, stabilize illness state and prevent recurrence.

The patient in the year 09 and the day 07 of 2022 has no cough, expectoration, wheeze and shortness of breath, does not smell and dry and wet type of the lung, so the disease is stable, has no recurrence and repetition, the vital signs are steady, spO2 is 95 percent (oxygen is not inhaled), the treatment is effective and discharged, and the patient is ordered to continue taking the Chinese medicine of 'AECOPD I prescription' outside the hospital to 'benefit qi and strengthen the body resistance, reduce phlegm and promote blood circulation, nourish yin and clear heat' so as to enhance the immunity and disease resistance, reduce the frequency of acute exacerbation so as to delay the deterioration of the lung function, the disease progress, improve the respiratory symptoms and exercise endurance and improve the life quality.

Claims

1. A medicament for treating chronic obstructive pulmonary disease at a stationary phase after acute exacerbation, characterized in that: the medicinal active ingredients of the composition are calculated according to the weight components: is prepared from 100-200 parts of ginseng, 50-150 parts of fritillaria thunbergii, 50-150 parts of semen trichosanthis, 50-150 parts of dried orange peel, 50-150 parts of poria cocos, 50-150 parts of rhizoma pinellinae praeparata, 30-90 parts of cortex moutan, 30-90 parts of red paeony root, 50-150 parts of radix scutellariae, 50-150 parts of rhizoma anemarrhenae, 10-50 parts of raw rheum officinale and 30-90 parts of raw liquorice.

2. The medicament for treating the stationary phase after acute exacerbation of chronic obstructive pulmonary disease according to claim 1, wherein: the medicinal active ingredients of the composition are calculated according to the weight components: is prepared from 120-180 parts of ginseng, 70-130 parts of fritillaria thunbergii, 70-130 parts of semen trichosanthis, 70-130 parts of dried orange peel, 70-130 parts of poria cocos, 70-130 parts of rhizoma pinellinae praeparata, 40-80 parts of cortex moutan, 40-80 parts of red paeony root, 70-130 parts of radix scutellariae, 70-130 parts of rhizoma anemarrhenae, 20-40 parts of raw rheum officinale, and 40-80 parts of raw liquorice.

3. The medicament according to claim 1 or 2 for the treatment of the stationary phase after acute exacerbation of chronic obstructive pulmonary disease, characterized in that: the medicinal active ingredients of the composition are calculated according to the weight components: is prepared from 150 parts of ginseng, 100 parts of fritillaria thunbergii, 100 parts of semen trichosanthis, 100 parts of dried orange peel, 100 parts of poria cocos, 100 parts of rhizoma pinellinae praeparata, 60 parts of cortex moutan, 60 parts of radix paeoniae rubra, 100 parts of radix scutellariae, 100 parts of rhizoma anemarrhenae, 30 parts of radix et rhizoma Rhei and 60 parts of radix glycyrrhizae.

4. A method for the preparation of a medicament for the treatment of post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to any one of claims 1-3, wherein: all the medicinal materials are weighed according to the proportion, combined with pharmaceutically acceptable auxiliary materials in the medicines, and processed according to the conventional preparation method to prepare corresponding medicinal preparations.

5. The method for preparing the medicine for treating the post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to claim 4, wherein: weighing the medicinal materials according to the proportion of the formula, soaking the medicinal materials in water, decocting, mixing the decoctions, uniformly mixing, concentrating, filtering while the decoction is hot, concentrating the filtrate into extract, combining with pharmaceutically acceptable auxiliary materials in the medicament, and processing according to a conventional preparation method to prepare the corresponding oral medicinal preparation.

6. The method for preparing the medicine for treating the post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to claim 5, wherein: the oral pharmaceutical preparation comprises a soft extract, granules, hard capsules, tablets or oral liquid.

7. The method for preparing the medicine for treating the post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to claim 6, wherein: the decoction is prepared by the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in 8 times of water for 0.5 hour, decocting the medicinal materials for 0.5 hour, adding the raw rhubarb according to the prescription proportion, decocting the medicinal materials for 0.5 hour, collecting decoction, adding 8 times of water into dregs, decocting the dregs for 1 hour, mixing the two decoctions, uniformly mixing, concentrating the mixture into an extract with the relative density of 1.15-1.20 when the mixture is hot, filtering the hot mixture, concentrating the filtrate to 70 ℃, adding refined honey with the relative density of 20%, adding the same times of warm water, stirring and dissolving the mixture, slowly adding the mixture into the extract, stirring the mixture uniformly, continuously heating the mixture with slow fire to obtain the ointment, and obtaining the ointment when a small amount of the ointment can be horizontally pulled into filaments or the ointment is dripped on paper without water marks.

8. The method for preparing the medicine for treating the post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to claim 6, wherein: the granule is prepared by the following steps: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in 10 times of water for 0.5 hour, decocting for 1 hour, adding the raw rhubarb according to the prescription proportion, decocting for 1 hour, collecting decoction, adding 10 times of water into dregs, decocting twice, each time for 0.5 hour, mixing the three decoctions, uniformly mixing, concentrating into 80% of the original medicinal liquid, filtering while the medicinal liquid is hot, concentrating the filtrate to 70 ℃ relative density of extract with 1.15-1.20, drying the extract at 70 ℃, crushing the extract into fine powder to obtain dry extract, taking 1 part of dry extract and 20% sucrose, granulating with 80% ethanol as a wetting agent, granulating, drying at 60 ℃, sieving with a 12-mesh sieve for 1 time, and sieving with a 60-mesh sieve to obtain the granule.

9. The method for preparing the medicine for treating the post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to claim 6, wherein: the capsules were prepared as follows: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in 12 times of water for 0.5 hour, decocting for 0.5 hour, adding the raw rhubarb according to the prescription proportion, decocting for 0.5 hour, collecting decoction, adding 12 times of water into dregs, decocting twice, each time for 0.5 hour, combining the three decoctions, uniformly mixing, concentrating into 70% of the original medicinal liquid, filtering when the medicinal liquid is hot, concentrating the filtrate into an extract with relative density of 1.15-1.20 at 70 ℃, drying at 70 ℃ into dry extract, pulverizing into fine powder, adding 10% of starch and 3% of microcrystalline cellulose, uniformly mixing, granulating with 75% of ethanol, drying, granulating, and filling into capsules to obtain the Chinese medicinal capsule.

10. The method for preparing the medicine for treating the post-acute exacerbation stationary phase of chronic obstructive pulmonary disease according to claim 6, wherein: the tablets were prepared as follows: weighing all the medicinal materials except the raw rhubarb according to the prescription proportion, soaking the medicinal materials in water for 0.5h, decocting for 1h, adding the raw rhubarb according to the prescription proportion, decocting for 1h, collecting decoction, adding water for 6 times of decoction for 1.5 h, mixing the three decoction, concentrating into an extract with the relative density of 1.15-1.20 when the raw medicinal liquid is 80%, filtering when the filtrate is concentrated to 70 ℃, drying the extract at 70 ℃, crushing the extract into fine powder to obtain a dry extract, taking the dry extract, adding 15% starch and 1% talcum powder, mixing uniformly, granulating with 10% starch slurry as a wetting agent, drying, tabletting, and film coating to obtain the tablet.